Published in Women's Health Weekly, May 30th, 2002
The agent, difluoromethylornithine (DFMO), is an antiangiogenic therapy that also inhibits the action of the enzyme ornithine decarboxylase, according to the authors of a multicenter research study. In preliminary trials to establish the drug's safety, it has reduced cervical intraepithelial neoplasia (CIN) 3 lesions by half, the researchers say. The group has now elucidated the way DFMO works by studying immortalized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.